anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Iron deficiency and iron deficiency anaemia are frequently under-recognised in chronic conditions with non-specific symptoms, including fatigue. This study aimed to assess the prevalence of iron deficiency with or without anaemia in chronic pain patients, and the association between iron deficiency status, fatigue and health-related quality of life. Eighty-two patients attending chronic pain outpatient appointments were recruited into this cross-sectional study. Iron studies and haemoglobin were determined from venous blood samples. Participants' health-related quality of life was assessed with the 36-item short form survey and fatigue with the functional assessment of chronic illness therapy fatigue scale. Iron deficiency was prevalent in 58.8% of patients and 2.5% met the criteria for iron deficiency anaemia. There was no significant association between iron deficiency status and the functional assessment of chronic illness therapy fatigue scale score or 36-item short form survey domain scores. There was a high prevalence of iron deficiency in this group of chronic pain patients, while the prevalence of iron deficiency anaemia was low. There was no statistically significant association found between iron deficiency status and fatigue or quality of life measures.
FIELD: medicine, gynecology. SUBSTANCE: pseudoerosion of uterine cervix should be treated with the flow of plasmochemical sodium oxide for 30-60 sec followed by carrying out application with "Sanguicol" collagen sponge. Procedures are conducted twice weekly, total quantity of procedures corresponds to 8-10. The method enables to exclude hemorrhages and conduct therapy at any phase of menstrual cycle. EFFECT: higher efficiency of therapy. 1 ex
Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (\>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be \>10mg.
The present invention relates to a toxin reducing addiction removing preparation of cigarette with a health care function. The present invention comprises a toxin reducing water agent additive sprayed in tobacco shreds and an oral administration health care pill attached in a tobacco case, wherein the toxin reducing water agent additive and the oral administration health care pill are mutually associated and complementary and form an entity. The area for reducing toxin of the preparation is wide, and the range is large. Harmful substances, such as nicotine, tar, carbon monoxide, nitrogen oxide, poisonous metal, nitrosamine, etc., in tobacco smoke can be reduced. For example, the nicotine content can be reduced by 90 to 97%, and the tar content can be reduced by 75 to 85%. The preparation has the wide function range for preventing diseases and health care. The preparation can prevent various cancers, cardiovascular diseases, cerebral vessel diseases, respiratory system diseases, and other diseases which are caused by smoking, and the effect is clear. The present invention adopts vitamins and trace elements which are necessary for a human body as main components, and through the enzymatic conversion and the biochemistry action in the human body, addiction caused substances, such as dopamine and glutaminic acid, in a brain are reduced. Therefore, the addiction removing function is scientific, safe and effective. The present invention provides a favorable condition for stopping smoking for a person who has a stop smoking desire.
Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
A randomized, controlled, cross-over study designed to examine the post-prandial glycaemic response, metabolism of bioactives and appetite related sensations to 20% incorporation of yellow pea flour (untreated, heat treated with 0% moisture and heat treated with 10% moisture) into bread will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. Eligible participants who have provided consent will be asked to attend 4 clinic visits in a fasted state. Participants will be given bread containing 20% yellow pea flour at 3 visits and bread with 100% wheat flour at 1 visit. At each visit participants will provide 7 venous blood samples via indwelling catheter, 7 capillary blood samples via finger poke, 2 urine samples, 5 questionnaires about their appetite and a questionnaire about the acceptability of the products. Each visit will last approximately 3h and be separated by 3-14 days.
Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: End-stage kidney disease (ESKD) carries a significant financial burden due to the need for hemodialysis (HD). Many HD patients do not achieve optimal dialysis, particularly in developing countries like Indonesia where HD is performed twice a week. To answer this issue, a study was conducted at Dr. Sardjito hospital, Indonesia to investigate the effectiveness of intradialysis aerobic exercise in improving dialysis adequacy and quality of life in conventional HD patients.
METHODS: This study is an experimental design with a pre-test-post-test control group. ESKD with HD patient was divided into treatment and control groups. The intervention group was subjected to 30 min of intradialysis aerobic exercise using an ergocycle within the first 2 h of the HD sessions, while the control group received regular care. Both groups were followed for 12 weeks. Dialysis adequacy is measured using Kt/V and Urea Reduction Ratio (URR). Quality of life is assessed using KDQOL-36 questionnaire.
RESULTS: There was a significant increase in Kt/V and URR (%) in the intervention group compared to the control group, (0.122 ± 0.151 vs  - 0.135 ± 0.176, p < 0.001) and (2.627 ± 4.634 vs  - 2.620 ± 3.949, p < 0.001), respectively. In addition, quality of life also improved significantly with KDQOL-36 summary score was significantly higher 73.47 (39.44-89.31) to 80.97 (43.06-92.36); p = 0.007) in the intervention group. Multivariate analysis showed that intradialysis exercise (p = 0.001), female gender (p = 0.044), and intradialysis diastolic pressure (p = 0.018) can significantly affect Kt/V changes.
CONCLUSION: Intradialytic aerobic exercise for 12 weeks effectively improves dialysis adequacy and quality of life in routine HD patients. This suggests an opportunity for routine deployment, especially when HD resources are limited. However, further studies are needed to investigate additional efficacy aspects and improve exercise protocols for specific ESKD patients.
TRIAL REGISTRATION: TCTR202403270002 (retrospectively registered on March 27, 2024).
Aneurysmal subarachnoid hemorrhage is an acute cerebrovascular disease with high disability and mortality. We intended to explore the association between levels of erythrocytes in cerebrospinal fluid at different times of hemorrhage and the outcome of patients. One retrospective study including 216 patients with aneurysmal subarachnoid hemorrhage undergoing surgeries in the First Affiliated Hospital of Yangtze University from January 2020 to July 2023 was carried. The univariable analysis and multivariable logistic regression analysis were used for factors associated with poor outcome. The level of erythrocytes in cerebrospinal fluid on the 1st postoperative day in patients with poor outcome was 311 × 103/µL, significantly higher than patients with good outcome (108 × 103/µL), P < .001. The level of erythrocytes in cerebrospinal fluid on 7th postoperative day was 86.5 × 103/µL, also significantly higher than patients with good outcome (26.0 × 103/µL). The multivariable logistic regression analysis results showed that erythrocytes in cerebrospinal fluid on the 1st postoperative day (≥177 × 103/µL) and on the 7th postoperative day (≥53.5 × 103/µL) were possibly associated with poor outcome in aneurysmal subarachnoid hemorrhage patients. Treatment with tranexamic acid and continuous lumbar drainage did not result in a decrease of erythrocytes in cerebrospinal fluid. Higher erythrocytes in cerebrospinal fluid on the 1st and 7th postoperative days were associated with poor outcome in aneurysmal subarachnoid hemorrhage patients.
BACKGROUND: Acute promyelocytic leukemia (APL) is the sub-type of Acute myeloid leukemia (AML) which is described by differentiation block at promyelocytic stage and t(15; 17) translocation with All trans retinoic acid (ATRA) and arsenic trioxide (ATO) as standard treatments. Chronic myeloid leukemia (CML) translocation t (19; 22) causes a rise in granulocytes and their immature precursors in the blood. Different mutations cause resistance to first-line tyrosine kinase therapies in CML. Beside drug resistance, leukemia stem cells (LSC) are critical resources for relapse and resistance in APL and CML. The drug toxicity and resistant profile associated with LSC and current therapeutics of APL and CML necessitate the development of new therapies. Imidazoles are heterocyclic nitrogen compounds with diverse cellular actions. The purpose of this research was to assess the anti-leukemic properties of four novel imidazole derivatives including L-4, L-7, R-35, and R-NIM04.
METHODS AND RESULTS: Pharmacological and biochemical approaches were used which showed that all four imidazole derivatives interfere with the NB4 cells proliferation, an APL cell line, while only L-7 exhibit anti-proliferative activity against K562 cells, a CML cell line. The anti-proliferative effect of imidazole derivatives was linked to apoptosis induction. Further real-time polymerase chain reaction (RT-PCR) analysis revealed downregulation of AXL-Receptor Tyrosine Kinase (AXL-RTK) and target genes of Wnt/beta-catenin pathway like c-Myc, Axin2 and EYA3. An additive effect was observed after combinatorial treatment of L-7 with standard drugs ATRA or Imatinib on the proliferation of NB4 and K562 cells respectively which was related to further downregulation of target genes of Wnt/beta catenin pathway.
CONCLUSION: Imidazole derivatives significantly reduce proliferation of NB4 and K562 cells by inducing apoptosis, down regulating of AXL-RTK and Wnt/β-catenin target genes.
All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
FIELD: biotechnology.SUBSTANCE: method of culturing tumour stem cells of glioblastoma is disclosed. The method comprises selecting such cells, inoculation and incubation in the culture vessel. At least 0.5 g glioblastoma material is selected, which is crushed to pieces no larger than 5x5x5 mm, which are not allowed to dry. Then, the tumour stem cells are isolated from the selected material and they are precipitated. Then they are mixed with the medium for culturing mammalian cells, the cells are resuspended and precipitated into culture flasks. Culturing is carried out to form a monolayer. Then enzymatic dissociation is carried out for 10 minutes at 37°C by 0.05% trypsin-ethylenediaminetetraacetic acid added in a ratio of 1:4, centrifugation for 3 min at 1200 rev/min. Then fresh medium is added, resuspended, re-cultured using the cell suspensions containing no less than 85-95% viable cells, and treated with a fluorescent marker fluorescent under ultraviolet radiation. The invention can be used in laboratory pre-clinical molecular-biological evaluation of the therapeutic efficacy of anticancer preparation obtained by targeted modification of transcriptomic profile of hematopoietic stem and progenitor cells (SC and PC) used for high-tech complex treatment of preferably malignant glial brain tumours.EFFECT: improvement of the method.4 cl, 2 ex
ETHNOPHARMACOLOGICAL RELEVANCE: The Northeastern state of India is known for its remarkable biodiversity and untapped medicinal resources. Jussiaea repens L., commonly known as water primrose, is a plant found in this region that has been traditionally used by indigenous communities for various purposes. It has been employed to treat skin ulcerations, bone fractures, rheumatism, stomach pain, and intestinal worms. Despite its long-standing ethnopharmacological usage, there is limited scientific research on the bioactivity of Jussiaea repens L. However, preliminary studies have shown its potential antioxidant properties and cytotoxicity against cancer cells. Further exploration of its medicinal properties, particularly its potential as an anti-inflammatory agent, is warranted.
AIM OF THE STUDY: This study aimed to investigate the anti-inflammatory properties of Jussiaea repens L., a plant species found in the biodiverse Northeastern region of India. The plant has been traditionally used by indigenous communities for various ailments. By utilizing zebrafish as an animal model and evaluating its effects in different inflammation models, the study aimed to uncover the plant's potential as an anti-inflammatory agent. The research contributes to the scientific understanding of this traditional remedy and its potential therapeutic applications.
METHODS: Jussiaea repens L. extract was obtained from the stem and leaves using methanol as the solvent. Zebrafish embryos were used for in vivo assays. The anti-inflammatory study included two models: CuSO4-induced inflammation and tail wounding followed by bacterial lipopolysaccharide-induced inflammation. The activities of catalase (CAT) and superoxide dismutase (SOD) were measured in CuSO4-induced inflammation. Leukocyte migration at the injury site was observed in the tail wounding model. The extract's inhibition of the 15-LOX enzyme was assessed. All procedures followed established protocols and ethical guidelines.
RESULTS AND CONCLUSION: Jussiaea repens L. extract exhibited anti-inflammatory activity in two in vivo zebrafish models: CuSO4-induced inflammation and tail wounding combined with bacterial lipopolysaccharide-induced inflammation. The extract reduced mortality rates and showed antioxidant effects by increasing catalase (CAT) and superoxide dismutase (SOD) activities in the CuSO4 model. In the tail wounding model, the extract reduced leukocyte migration in a concentration-dependent manner. Additionally, the extract demonstrated dose-dependent inhibition of the 15-LOX enzyme in the in vitro assay. These results suggest that Jussiaea repens L. extract possesses anti-inflammatory properties and inhibits the 15-LOX enzyme.
The onset of pharmacological action of metoclopramide is 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours. In patients with gastroesophageal reflux and low LESP (lower esophageal sphincter pressure), single oral doses of metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (the largest dose tested). The increase in LESP from a 5 mg dose lasts about 45 minutes and that of a 20 mg dose lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg.

The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg taken four times a day.

As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. For gastroparesis, the usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond within different time intervals.
Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough\[needs update\] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
Papillary thyroid cancer is associated with lymph node metastasis and tumor recurrence that need repeated surgery, entailing surgical challenges with a high risk of complications such as nerve damage and bleeding. Magseed is a metal coil used to detect non-palpable lesions and is an established modality in breast cancer surgery. In this case series, we explore the feasibility of Magseed in metastasis surgery of papillary thyroid cancer. Under the guidance of ultrasonography, Magseed is injected into the target tissue and intraoperatively detected with a handheld magnetometer probe, Sentimag®. Five patients with recurrence of papillary thyroid cancer were operated on with focused Magseed-guided localization. All patients had repeated surgery and radioiodine treatments. Four of the patients had lymph node metastasis hidden in the fibrosis, and one patient had recurrent tumor tissue on the left side of the larynx. Magseed was easy to use, safe, and precise in detecting the target tissue.
BACKGROUND: Valid and generalizable data on the clinical features and surgical strategies for retroperitoneal liposarcoma (LPS) involving the kidney capsule remain scarce. This study aimed to investigate the clinical characteristics, morbidity, mortality, and long-term survival of patients with retroperitoneal LPS involving the kidney capsule.
METHODS: The authors analyzed a prospectively maintained database of patients who underwent surgical resection for retroperitoneal LPS between 2015 and 2020. The patients were categorized into kidney capsule or no kidney capsule groups based on the presence or absence of kidney capsule involvement. A kidney-sparing strategy for retroperitoneal LPS involving the kidney capsule was developed. The primary outcome measure was overall survival (OS). The cumulative event probability curve was estimated using the Kaplan-Meier, and differences between groups using the Log-Rank.
RESULTS: The study population consisted of 128 patients-54 with and 74 without kidney capsule involvement. Of these patients, 70 were female (54.7%) and 58 were male (45.3%), with a median age of 55. The median follow-up duration was 35 months. Postoperative morbidity, mortality, length of hospital stay, length of ICU stay, OS, and recurrence-free survival (RFS) did not differ significantly between the groups. Eleven patients developed postoperative acute kidney injury (AKI), and one patient required dialysis during the follow-up period. In multivariable logistic regression analysis, only nephrectomy was independently associated with postoperative AKI. Subgroup analysis of patients with kidney capsule involvement showed that nephrectomy did not improve OS or RFS but significantly decreased postoperative estimated glomerular filtration rate.
CONCLUSION: Nephrectomy was associated with an increased risk of postoperative AKI after retroperitoneal LPS resection. A kidney-sparing strategy for retroperitoneal LPS involving the kidney capsule achieved optimal clinical outcomes.
PURPOSE:An analgesic preparation for intravenous medication obtained by blending sulpyrine with sodium salicylate and allobarbital, having synergistic analgesic effect, having low toxicity and safety. CONSTITUTION:Sulpyrine is blended with sodium salicylate and allobarbital to give an analgesic preparation for intravenous injection. Especially 250mg sulpyrine, 350mg sodium salicylate and 10mg allobarbital are added to one tube with 10ml. The tital effect of sodium salicylate and sulpyrine is arithmetic, but the addition of allobarbital increases analgesic effect synergistically. The blending of central excitatory sodium salicylate and suplyrine and central inhibitory allobarbital reduces toxicity. This blended preparation shows the maximum effect by the minimum blended components in minimum amounts.
Octenidine or its salts, preferably octenidine dihydrochloride, which is intended for mutual administration of octenidine in solution with a polyalcohol compound (I), where optionally in addition to one or more aldehyde groups, provided that they form (cyclic) acetals with one of the hydroxy groups or one or more keto groups optionally as acetal with one of the hydroxy groups, optionally in addition to one or more carboxylic acid groups if (I) is a cyclic acetal or acetal, or a polymer, polyether and/or polyester, is claimed. Octenidine or its salts, preferably octenidine dihydrochloride, which is intended for mutual therapeutic administration of octenidine in solution with a polyalcohol compound of formula (H-C-OH) a(HO-C-OH) b(H-C-H) c (I), where optionally in addition to one or more aldehyde groups, provided that they form (cyclic) acetals with one of the hydroxy groups or one or more keto groups optionally as acetal with one of the hydroxy groups, optionally in addition to one or more carboxylic acid groups if (I) is a cyclic acetal or acetal, preferably with ring sizes of 5-7 atoms, or a polymer, polyether and/or polyester, provided that (I) exists as a polymer, polyether or polyester with at least two units of (I) if sum of a and b is 2 or 3, is claimed. a, b : whole number; and a+b : at least 2, preferably 3; and c : 0-2 to (a+b). Independent claims are included for: (1) a kit comprising (I) and octenidine or its salts, preferably octenidine dihydrochloride; (2) a composition in the form of a solution comprising (I) and octenidine or its salts, preferably octenidine dihydrochloride; and (3) an agent comprising a solution of octenidine or its salts and glucose at a concentration of 0.01-12, preferably 2.5-5 wt./vol.% and optionally a carrier, where octenidine is at a concentration of 0.0001-1, preferably 0.002-0.01 wt/wt.%. ACTIVITY : Vulnerary; Antimicrobial. MECHANISM OF ACTION : None given.
Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
The present invention relates to compositions and methods of using peroxisome proliferator-activated receptor-gamma (PPAR.gamma.) antagonists. In one embodiment, the present invention relates to compositions and methods for preparing and using such antagonist compositions. In another embodiment, the present invention provides for using PPAR-gamma antagonist compositions to treat disease. such as cancer. In other embodiments, the present invention provides for using PPAR-gamma antagonist and one or more additional anti-cancer agent compositions to treat cancer.